news
GSK halts Excedrin production due to manufacturing inconsistencies
GlaxoSmithKline has announced that it will not be manufacturing or distributing some of its Excedrin products after inconsistencies in ingredient transfer and weight.
List view / Grid view
Production
Filter the results
news
Global neoantigen cancer vaccine market to generate $1,826.1m revenue by 2030
A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.
news
Statement from the FDA on NDMA found in drugs outside the US
The FDA has released a statement on the investigations into the presence of nitrosamines in some drugs; highlighting that there are currently no recalls of metformin within the US.
article
Regulatory non-compliance business interruptions
Loss of manufacturing capability as a result of regulatory non-compliance can have a devastating impact on biopharma or medical device manufacturers. In this article, Jenny Yu shares real-life examples from the industry and highlights the downstream effects of these business interruptions.
webinar
Increased raw material verification capabilities with portable Raman and XRF instruments
29 October 2019 | By Thermo Fisher Scientific
This webinar explored the use of the Thermo Scientific™ handheld Raman analyser TruScan™ RM with TruTools™ on-board chemometrics to verify the identity of challenging raw materials.
news
Osteoarthritis therapeutics market to be worth $10.1bn by 2024, says report
A new report has said the osteoarthritis therapeutics market is estimated to grow due to rapid increase in the geriatric and obese population.
webinar
TOC fitness for purpose: How to ensure your TOC analyser is fit for compendial water & cleaning validation
19 September 2019 | By SUEZ
This webinar will present how to easily evaluate "fitness for purpose" of a TOC instrument for compendial water and cleaning validation applications based on USP and ICH Q2(R1).
news
Drug manufacturer planned to shred cGMP documents ahead of inspection
An Indian pharmaceutical company was planning to shred quality control records ahead of an FDA inspection, found officials.
article
The impact of counterfeit drugs in south and south-east Asia
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.
product
On-demand webinar: Get Merck’s winning combination for Air Monitoring in Isolators to stay compliant to ISO 14698
In this webinar, we will introduce you to the microbial environmental monitoring in production isolators. You will learn how to be compliant and ease your workflow.
product
On-demand webinar: Pyrogenic Risk in Pharma Process Webinar – from bioburden to pyrogens
Microbial risk in pharmaceutical process is not limited to living microorganisms and intact microbial cells.
Whitepapers/App Notes/Posters
Whitepaper: Stability testing blister packs inspected with Sepha’s VisionScan test method
It is a requirement of both US and EU regulations that pharmaceutical packaging operations demonstrate integrity. As technology-based solutions remain somewhat of an unknown quantity, this whitepaper tests the hypothesis that Sepha’s VisionScan test method is considered non destructive.
news
Pharmaceutical intermediates market to see growth
The global pharmaceutical intermediates market is likely to see year-on-year growth in 2019, by an estimated 3.6 percent rate.
Whitepapers/App Notes/Posters
Whitepaper: Influence of different lubricants on tabletting characteristics and dissolution behaviour
Lubricants have a far more wide-reaching impact on the characteristics of the finished tablet than merely easing their means of production. A study was carried out to investigate precisely what those effects were.
webinar
The role of an integrated LIMS solution on supporting data integrity in current cGMP environments
14 May 2019 | By Abbott Informatics
Understand the role of data integrity in current good manufacturing practice for drugs as required in 21 CFR parts 210, 211, and 212.